Testosterone
Posted: Wed Mar 29, 2006 8:58 am
My Neuro is presenting the following paper at the AAN convention next week in San Diego. Interesting, given the discussions here on endocrine involvement in MS. BTW, I am a male PPMSer with low Testosterone...
[P04.103] Decreased Serum Testosterone Levels in Multiple Sclerosis
Elena V. Simon, Ilir Topalli, Amir Touray, Saud A. Sadiq, New York, NY
OBJECTIVE: To determine if serum testosterone levels are altered in multiple sclerosis (MS). BACKGROUND: MS disease severity and progression is likely affected by several factors. Hormonal changes are implicated due to a higher incidence in females, disease amelioration in pregnancy, and apparent disease acceleration in post-menopausal women and older men. Because testosterone has neuroprotective and immunomodulatory effects and is protective in experimental autoimmune encephalomyelitis, we investigated whether testosterone levels are altered in MS. DESIGN/METHODS: Total and free serum testosterone levels were obtained from 100 randomly selected clinically definite MS patients (68 females and 32 males). Patients were excluded if pregnant or nursing, taking hormone therapy or contraception, had infection, blood disorders, history of liver disease or recent steroid therapy. Patients were evaluated for disease activity. All analysis was double-blinded. Low testosterone levels were defined as 20 ng/dl in females and 295 ng/dl in males. RESULTS: Thirty-nine of 68 females (57%) and 14 of 32 males (44%) had decreased serum testosterone levels. These testosterone levels are much lower than the values seen in a normal population where only 5% would be expected to have decreased levels. A significant correlation of testosterone levels with change in EDSS was not shown in our patients. However, in male patients with ongoing disease progression, 60% had low testosterone levels suggesting a trend towards increased disease activity with lowered hormone levels. Similarly, in females with normal testosterone levels only 33% showed evidence of disease progression in the preceeding year, whereas 54% with low testosterone levels had active disease. CONCLUSIONS/RELEVANCE: Low testosterone levels occur in approximately 50% of patients with MS. In patients with low hormone levels, a relationship with increased disease activity was seen and needs to be confirmed for significance in a larger study. Treatment trials are also warranted. Supported by: Advisory Board of the MS Research Center of New York.
Category - MS and Related Diseases
SubCategory - Clinical Science
[P04.103] Decreased Serum Testosterone Levels in Multiple Sclerosis
Elena V. Simon, Ilir Topalli, Amir Touray, Saud A. Sadiq, New York, NY
OBJECTIVE: To determine if serum testosterone levels are altered in multiple sclerosis (MS). BACKGROUND: MS disease severity and progression is likely affected by several factors. Hormonal changes are implicated due to a higher incidence in females, disease amelioration in pregnancy, and apparent disease acceleration in post-menopausal women and older men. Because testosterone has neuroprotective and immunomodulatory effects and is protective in experimental autoimmune encephalomyelitis, we investigated whether testosterone levels are altered in MS. DESIGN/METHODS: Total and free serum testosterone levels were obtained from 100 randomly selected clinically definite MS patients (68 females and 32 males). Patients were excluded if pregnant or nursing, taking hormone therapy or contraception, had infection, blood disorders, history of liver disease or recent steroid therapy. Patients were evaluated for disease activity. All analysis was double-blinded. Low testosterone levels were defined as 20 ng/dl in females and 295 ng/dl in males. RESULTS: Thirty-nine of 68 females (57%) and 14 of 32 males (44%) had decreased serum testosterone levels. These testosterone levels are much lower than the values seen in a normal population where only 5% would be expected to have decreased levels. A significant correlation of testosterone levels with change in EDSS was not shown in our patients. However, in male patients with ongoing disease progression, 60% had low testosterone levels suggesting a trend towards increased disease activity with lowered hormone levels. Similarly, in females with normal testosterone levels only 33% showed evidence of disease progression in the preceeding year, whereas 54% with low testosterone levels had active disease. CONCLUSIONS/RELEVANCE: Low testosterone levels occur in approximately 50% of patients with MS. In patients with low hormone levels, a relationship with increased disease activity was seen and needs to be confirmed for significance in a larger study. Treatment trials are also warranted. Supported by: Advisory Board of the MS Research Center of New York.
Category - MS and Related Diseases
SubCategory - Clinical Science